At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders.
We are currently developing three product candidates under our INOpulse program, a proprietary pulsatile nitric oxide delivery device. The first is for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), the second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and the last is for pulmonary hypertension associated with sarcoidosis (PH-Sarc). All three programs are currently in Phase 2 development.
Source
